Potential Weak Interaction
Emtricitabine/Tenofovir-DF (FTC/TDF, PrEP)
Quality of Evidence:
Juluca (dolutegravir/rilpivirine) is indicated for use as a complete regimen for the treatment of HIV-1 infection. However, in specific clinical situations where an intensification of HIV treatment is needed, coadministration with emtricitabine/tenofovir-DF would be possible from a pharmacokinetic standpoint as no clinically relevant drug-drug interaction is expected.
Juluca should not be administered with other antiretroviral medicinal products for the treatment of HIV.
Juluca Summary of Product Characteristics, ViiV Healthcare Ltd, May 2018.
Because Juluca is a complete regimen, coadministration with other antiretroviral medications for the treatment of HIV-1 infection is not recommended.
Juluca US Prescribing Information, ViiV Healthcare Ltd, September 2018.
View all available interactions with
Emtricitabine/Tenofovir-DF (FTC/TDF, PrEP) by clicking